• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

MUT-TP53 2.0:一种用于分析人类癌症中 TP53 突变的新型多功能矩阵。

MUT-TP53 2.0: a novel versatile matrix for statistical analysis of TP53 mutations in human cancer.

机构信息

Karolinska Institute Department of Oncology-Pathology Cancer Center Karolinska, Stockholm, Sweden.

出版信息

Hum Mutat. 2010 Sep;31(9):1020-5. doi: 10.1002/humu.21313.

DOI:10.1002/humu.21313
PMID:20572016
Abstract

Analysis of the literature reporting p53 mutations shows that 8% of report display typographical mistakes with a notable increase in recent years. These errors are sometimes isolated, but in some cases, they concern several or even all mutations described in a single article. Furthermore, some works report unusual profile of p53 mutations whose accuracy is difficult to assess. To handle these problems we have developed MUT-TP53 2.0, an accurate and powerful tool that will automatically handle p53 mutations and generate tables ready for publication that will lower the risk of typographical errors. Furthermore, using functional and statistical information issued from the UMD p53 database, it allows to assess the biological activity and the likelihood of every p53 mutant.

摘要

分析报告 p53 突变的文献表明,8%的文献存在印刷错误,且近年来显著增加。这些错误有时是孤立的,但在某些情况下,它们涉及单个文章中描述的多个甚至所有突变。此外,一些研究报告了不寻常的 p53 突变谱,其准确性难以评估。为了解决这些问题,我们开发了 MUT-TP53 2.0,这是一个准确而强大的工具,它将自动处理 p53 突变,并生成准备发表的表格,从而降低印刷错误的风险。此外,它还利用 UMD p53 数据库提供的功能和统计信息,评估每个 p53 突变体的生物活性和可能性。

相似文献

1
MUT-TP53 2.0: a novel versatile matrix for statistical analysis of TP53 mutations in human cancer.MUT-TP53 2.0:一种用于分析人类癌症中 TP53 突变的新型多功能矩阵。
Hum Mutat. 2010 Sep;31(9):1020-5. doi: 10.1002/humu.21313.
2
The UMD TP53 database and website: update and revisions.UMD TP53数据库及网站:更新与修订
Hum Mutat. 2006 Jan;27(1):14-20. doi: 10.1002/humu.20269.
3
Meta-analysis of the p53 mutation database for mutant p53 biological activity reveals a methodologic bias in mutation detection.对p53突变数据库中突变型p53生物学活性的荟萃分析揭示了突变检测中的一种方法学偏差。
Clin Cancer Res. 2006 Jan 1;12(1):62-9. doi: 10.1158/1078-0432.CCR-05-0413.
4
The UMD-p53 database: new mutations and analysis tools.UMD-p53数据库:新突变与分析工具
Hum Mutat. 2003 Mar;21(3):176-81. doi: 10.1002/humu.10187.
5
MUT-TP53: a versatile matrix for TP53 mutation verification and publication.MUT-TP53:用于TP53突变验证与发表的通用矩阵。
Hum Mutat. 2006 Nov;27(11):1151-4. doi: 10.1002/humu.20395.
6
Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database.突变型p53功能特性对TP53突变模式和肿瘤表型的影响:来自国际癌症研究机构TP53数据库最新进展的经验教训
Hum Mutat. 2007 Jun;28(6):622-9. doi: 10.1002/humu.20495.
7
TP53 mutations in human cancer: database reassessment and prospects for the next decade.人类癌症中的 TP53 突变:数据库再评估及未来十年展望。
Adv Cancer Res. 2011;110:107-39. doi: 10.1016/B978-0-12-386469-7.00005-0.
8
TP53 mutations in human cancer: database reassessment and prospects for the next decade.人类癌症中的TP53突变:数据库重新评估及未来十年展望
Hum Mutat. 2014 Jun;35(6):672-88. doi: 10.1002/humu.22552.
9
[TP53 mutations and molecular epidemiology].[TP53 突变与分子流行病学]
Gan To Kagaku Ryoho. 2007 May;34(5):683-9.
10
TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes.人类癌症中的TP53突变:功能选择及其对癌症预后和结局的影响。
Oncogene. 2007 Apr 2;26(15):2157-65. doi: 10.1038/sj.onc.1210302.

引用本文的文献

1
Mutation or not, what directly establishes a neoplastic state, namely cellular immortality and autonomy, still remains unknown and should be prioritized in our research.无论是否发生突变,直接导致肿瘤状态(即细胞永生化和自主性)的因素仍然未知,这应该是我们研究中的优先事项。
J Cancer. 2022 Jul 4;13(9):2810-2843. doi: 10.7150/jca.72628. eCollection 2022.
2
Case Report: Complete Remission of a Patient With Metastatic Gastric Cancer Treated With Nivolumab Combined With Chemotherapy After Palliative Surgery.病例报告:一名转移性胃癌患者在姑息性手术后接受纳武单抗联合化疗治疗后完全缓解
Front Immunol. 2022 Jun 29;13:908558. doi: 10.3389/fimmu.2022.908558. eCollection 2022.
3
Characterization of acquired nutlin-3 resistant non-small cell lung cancer cells.
获得性耐Nutlin-3的非小细胞肺癌细胞的特征分析
Cancer Drug Resist. 2021 Mar 19;4(1):233-243. doi: 10.20517/cdr.2020.91. eCollection 2021.
4
SNP309 and SNP285 Act as Negative Prognostic Markers for Non-small Cell Lung Cancer Adenocarcinoma Patients.SNP309和SNP285作为非小细胞肺癌腺癌患者的不良预后标志物。
J Cancer. 2017 Jul 15;8(12):2154-2162. doi: 10.7150/jca.19254. eCollection 2017.
5
Low-burden TP53 mutations in chronic phase of myeloproliferative neoplasms: association with age, hydroxyurea administration, disease type and JAK2 mutational status.骨髓增殖性肿瘤慢性期低负担 TP53 突变:与年龄、羟基脲治疗、疾病类型和 JAK2 突变状态的关联。
Leukemia. 2018 Feb;32(2):450-461. doi: 10.1038/leu.2017.230. Epub 2017 Jul 24.
6
Towards Prognostic Profiling of Non-Small Cell Lung Cancer: New Perspectives on the Relevance of Polo-Like Kinase 1 Expression, the Mutation Status and Hypoxia.迈向非小细胞肺癌的预后分析:关于Polo样激酶1表达、突变状态与缺氧相关性的新观点
J Cancer. 2017 May 12;8(8):1441-1452. doi: 10.7150/jca.18455. eCollection 2017.
7
Immunomodulatory Function of the Tumor Suppressor p53 in Host Immune Response and the Tumor Microenvironment.肿瘤抑制因子p53在宿主免疫反应和肿瘤微环境中的免疫调节功能
Int J Mol Sci. 2016 Nov 19;17(11):1942. doi: 10.3390/ijms17111942.
8
Ultra-deep sequencing detects ovarian cancer cells in peritoneal fluid and reveals somatic TP53 mutations in noncancerous tissues.超深度测序可检测腹水中的卵巢癌细胞,并揭示非癌组织中的体细胞TP53突变。
Proc Natl Acad Sci U S A. 2016 May 24;113(21):6005-10. doi: 10.1073/pnas.1601311113. Epub 2016 May 5.
9
Effector T Cells Abrogate Stroma-Mediated Chemoresistance in Ovarian Cancer.效应T细胞消除卵巢癌中基质介导的化疗耐药性。
Cell. 2016 May 19;165(5):1092-1105. doi: 10.1016/j.cell.2016.04.009. Epub 2016 Apr 28.
10
New perspective on targeting the tumor suppressor p53 pathway in the tumor microenvironment to enhance the efficacy of immunotherapy.靶向肿瘤微环境中肿瘤抑制因子 p53 通路以增强免疫疗法疗效的新视角。
J Immunother Cancer. 2015 Mar 24;3:9. doi: 10.1186/s40425-015-0053-5. eCollection 2015.